Apricus Biosciences + Ferring Pharma announce approval in the UK for Vitaros (alprostadil topical cream) to treat erectile dysfunction .

Apricus Biosciences, Inc. has announced that Ferring Pharmaceuticals, the Company's new partner in the United Kingdom, has received the United Kingdom marketing authorization for Vitaros (alprostadil topical cream) to treat erectil;e dysfunction Under the terms of the agreement, Apricus has received a total of $4.5 million in upfront payments from Ferring, in addition to a regulatory milestone payment of $1.6 million. Apricus is eligible to receive up to an additional $28 million in regulatory, launch and sales milestones, plus royalties on future net sales.

Earlier this year, the Company expanded its exclusive Vitaros distribution agreement with Ferring International S.A. in Latin America. Now the deals include Germany, Austria, Belgium, Denmark, Finland, Iceland, Luxembourg, Norway, the Netherlands, Sweden, Switzerland and certain countries in Asia, previously Sandoz's territories, the United Kingdom, previously Takeda's territory, and Korea.